Tislelizumab in combination for untreated advanced non-small-cell lung cancer (terminated appraisal)
Technology appraisal
Reference number: TA1058
Published:
For information, tislelizumab has now been acquired by the company Beigene. NICE are liaising with the company regarding appropriate timelines for this appraisal and further information will be available in due course.